10-K/A: cbdMD, Inc. Files Amended 10-K Report Including Part III Information

cbdMD, Inc. has filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive compensation, and corporate governance.

Summary

• cbdMD, Inc. filed an amendment to its annual report on Form 10-K for the fiscal year ended September 30, 2023.
• This amendment, designated as Form 10-K/A, includes information required by Part III of Form 10-K, which was previously omitted from the original filing.
• The omitted information pertains to directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and accounting fees.
• The company's common stock outstanding as of January 18, 2024, is 3,045,092 shares.
• The amendment includes new certifications from the principal executive officer and principal financial officer as required by the Sarbanes-Oxley Act of 2002.
• The company has not updated the disclosures to reflect any events that occurred after the original filing date.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing, with some positive aspects related to governance and compensation, but also some negative aspects related to the need for an amendment and past issues. Overall, the sentiment is neutral to slightly positive.

Positives

• The company has a clear corporate governance framework with independent directors on key committees.
• The company has established compensation programs designed to attract and retain qualified executives.
• The company has a clawback provision in executive employment agreements.
• The company has an anti-hedging policy in place for officers, directors, and employees.
• The company has a pre-approval policy for all fees charged by its independent registered public accounting firm.

Negatives

• The company had to amend its original 10-K filing to include omitted information.
• The company's former CEO was involved in SEC litigation, which impacted a related transaction.
• The company's former President resigned in February 2023.
• The company's financial statements are not included in this amendment.

Risks

• The company faces risks including operational, regulatory, strategic, reputation, credit, interest rate, and liquidity risks.
• The company's ability to continue as a going concern is a primary risk.
• Increasing the customer base, diversifying sales, and improving profitability are key challenges.
• The company's independent directors may conduct risk assessments if there is a conflict with management.

Future Outlook

The company has not updated the disclosures to reflect any events that occurred after the original filing date.

Management Comments

• T. Ronan Kennedy, Interim Chief Executive Officer, certified that the report does not contain any untrue statement of a material fact.
• The board of directors recognizes that Dr. Swift is a minority, in keeping with the company's commitment to increase diversity on the board.

Industry Context

The company operates in the CBD industry, which is subject to evolving regulations and market dynamics. The company's focus on compliance and corporate governance is important in this context.

Comparison to Industry Standards

• The company's board structure, with independent directors on key committees, aligns with best practices for public companies.
• The company's compensation programs are designed to be competitive, which is a common practice in the industry.
• The company's audit and tax fees are comparable to other companies of similar size and complexity.
• The company's risk management approach is consistent with industry standards, addressing key risks such as operational, regulatory, and financial risks.
• The company's use of equity compensation plans is a common practice to align the interests of employees and shareholders.

Management Changes

Legal Proceedings

• The company's former CEO was involved in SEC litigation, which impacted a related transaction.

Related Party Transactions

• In September 2020, the company purchased a membership interest in Adara Sponsor LLC for $250,000, which was later sold for $1,000,000.
• Dr. Sibyl Swift is employed by the company at an annual salary of $240,000 in addition to her board compensation.

Stakeholder Impact

• Shareholders are provided with additional information regarding the company's governance and compensation practices.
• Employees are subject to the company's anti-hedging policy.
• The company's commitment to diversity on the board may positively impact stakeholders.

Next Steps

• The company will continue to operate under its established corporate governance framework.
• The company will continue to monitor and manage its identified risks.
• The company will continue to comply with all applicable regulations and reporting requirements.

Key Dates

Keywords

cbdMD, Form 10-K, amendment, corporate governance, executive compensation, directors, financial reporting, audit committee, Sarbanes-Oxley, equity compensation